Literature DB >> 9281435

The effect of CY1503, a sialyl Lewisx analog blocker of the selectin adhesion molecules, on infarct size and "no-reflow" in the rabbit model of acute myocardial infarction/reperfusion.

Y Birnbaum1, M Patterson, R A Kloner.   

Abstract

CY1503, an analogue of sialyl-Lewisx, is an inhibitor of the selectin adhesion molecules. CY1503 has been found to limit myocardial infarct size in canine and feline models. However, the effect of CY1503 on the "no-reflow" phenomenon is still unknown. Anesthetised rabbits were subjected to 30 min of coronary artery occlusion and 4 h of reperfusion. Protocol 1: after 27 min of ischemia, rabbits were randomised to an iv bolus of either CY1503 (30 mg/kg) (n=9) or saline (n=9). Protocol 2: rabbits were randomly given two iv boluses of CY1503 (30 mg/kg) (n=6) or saline (n=6), administered after 10 and 25 min of ischemia. Protocol 3: after 27 min of ischemia rabbits were randomly given an iv bolus of CY1503 (30 mg/kg) (n=6) and infusion of 20 mg/kg over 4 h or saline bolus+infusion (n=6). Regional myocardial blood flow (RMBF) was assessed after 30 min and 4 h of reperfusion. The risk zone (RZ) was assessed by blue dye and the necrotic zone (NZ) by tetrazolium staining. RMBF: protocol 1: RMBF in the RZ was 2.19+/-0.33 v 2. 34+/-0.34 ml/g/min in CY1503 and controls at 30 min (P=0.75), and 0. 43+/-0.07 v 0.41+/-0.08 at 4 h of reperfusion (P=0.85). The corresponding results for protocol 2 were 1.77+/-0.29 v 1.53+/-0.34 at 30 min (P=0.61) and 0.53+/-0.16 v 0.91+/-0.55 at 4 h (P=0.53). RMBF in RZ in protocol 3 were 1.52+/-0.25 v 1.32+/-0.20 at 30 min (P=0.56) and 0.30+/-0.05 v 0.29+/-0.09 (P=0.90) after 4 h of reperfusion. The RZ was similar in both groups in all protocols. The NZ/RZ ratio was comparable in the CY1503 and control group in all three protocols (0.32+/-0.04 v 0.37+/-0.06, 0.37+/-0.08 v 0.33+/-0. 07, and 0.51+/-0.05 v 0.38+/-0.05 in protocols 1, 2, and 3, respectively). CY1503 did not limit infarct size or prevent the "no-reflow" phenomenon in the rabbit.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9281435     DOI: 10.1006/jmcc.1997.0393

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  8 in total

Review 1.  Adhesion molecules in inflammatory diseases.

Authors:  R González-Amaro; F Díaz-González; F Sánchez-Madrid
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

2.  Pharmacological evidence that inducible nitric oxide synthase is a mediator of delayed preconditioning.

Authors:  J Imagawa; D M Yellon; G F Baxter
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

Review 3.  The immune system and cardiac repair.

Authors:  Nikolaos G Frangogiannis
Journal:  Pharmacol Res       Date:  2008-06-24       Impact factor: 7.658

4.  Plasma calprotectin was associated with platelet activation and no-reflow phenomenon in acute coronary syndrome.

Authors:  Nian-Peng Song; Xiao-Wen Zhen; Liu-Dong Li; Lin Zhong; Hua Wang; Yi An
Journal:  BMC Cardiovasc Disord       Date:  2020-10-09       Impact factor: 2.298

5.  The inflammatory response and cardiac repair after myocardial infarction.

Authors:  Deuk-Young Nah; Moo-Yong Rhee
Journal:  Korean Circ J       Date:  2009-10-28       Impact factor: 3.243

Review 6.  Mechanisms and mediators of inflammation: potential models for skin rejection and targeted therapy in vascularized composite allotransplantation.

Authors:  Theresa Hautz; Dolores Wolfram; Johanna Grahammer; Ravi Starzl; Christoph Krapf; Johann Pratschke; W P Andrew Lee; Gerald Brandacher; Stefan Schneeberger
Journal:  Clin Dev Immunol       Date:  2012-09-19

7.  Sphingolipids: a potential molecular approach to treat allergic inflammation.

Authors:  Wai Y Sun; Claudine S Bonder
Journal:  J Allergy (Cairo)       Date:  2012-12-18

8.  Inhibitors of selectin functions in the treatment of inflammatory skin disorders.

Authors:  Michael P Schön
Journal:  Ther Clin Risk Manag       Date:  2005-09       Impact factor: 2.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.